November 21, 2026
$RichWire Markets and money, explained simply
LIVE
Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results

AstraZeneca Gains Dual US and European Approvals for Rare Disease and Oncology Treatments

🏢 Companies 2 min read 👁 4

AstraZeneca shares rose 0.73% to $185.78 in premarket trading after securing major regulatory clearances in the US and EU for its rare disease drug Klygefa and an oncology combination regimen.

AstraZeneca Gains Dual US and European Approvals for Rare Disease and Oncology Treatments🏢Companies

Photo: Benzinga

Key points

  • AstraZeneca shares traded up 0.73% to $185.78 in premarket activity.
  • Klygefa received US and EU clearance for generalized myasthenia gravis.
  • Imfinzi combination therapy secured FDA approval for muscle-invasive bladder cancer.

Pharmaceutical giant AstraZeneca Plc saw its shares climb 0.73% to $185.78 during premarket trading following a string of regulatory approvals across both the United States and the European Union. The agencies cleared the company's rare neuromuscular disease treatment and an oncology regimen aimed at bladder cancer.

The U.S. Food and Drug Administration and European authorities greenlit Klygefa, developed by Alexion, AstraZeneca Rare Disease, for adults suffering from anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. In the EU, the therapy was authorized as an add-on to standard care. Klygefa functions as a dual-binding nanobody C5 inhibitor, enabling patients to administer the medication themselves via a once-weekly subcutaneous autoinjector. Approval was supported by data from the pivotal PREVAIL Phase 3 trial.

Separately, the FDA cleared an Imfinzi combination regimen for patients with muscle-invasive bladder cancer who are unable or unwilling to take cisplatin-based chemotherapy. Approximately 16,000 U.S. patients are projected to undergo treatment for this condition in 2026, with up to half unable to tolerate standard cisplatin due to existing health issues or kidney impairment. Data from the VOLGA Phase 3 trial demonstrated that the perioperative regimen reduced the risk of disease progression, recurrence, missed surgery, or death by 49% compared to standard surgery approaches.

What to watch next: Monitor upcoming decisions from regulators in China and other international markets where submissions for Klygefa remain under review.

Source Benzinga — benzinga.com/news/fda/26/11/63285561/astrazeneca-secures-dual-rare-… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.